Minerva Neurosciences Inc (NERV) reported quarterly earnings results on Thursday, Aug-4-2016. The company said it had a profit of $-0.18 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.12. Analysts had a consensus of $-0.30. During the same quarter in the previous year, the company posted $-0.27 EPS.
Many Wall Street Analysts have commented on Minerva Neurosciences Inc. Minerva Neurosciences Inc was Resumed by Jefferies to “Buy” on May 12, 2016.
Minerva Neurosciences Inc closed down -0.2 points or -1.79% at $10.98 with 2,27,391 shares getting traded on Tusday. Post opening the session at $11.21, the shares hit an intraday low of $10.591 and an intraday high of $11.26 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on Jun 21, 2016, David Kupfer (director) purchased 55,635 shares at $10.84 per share price.
Minerva Neurosciences Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. Its lead product candidate is MIN-101 a compound for the potential treatment of patients with schizophrenia. Its product pipeline also includes MIN-117 MIN-202 and MIN-301. MIN-101 is a compound it is developing for the treatment of patients with schizophrenia. MIN-117 is a compound for the potential treatment of patients suffering from major depressive disorder (MDD). MIN-202 is a selective orexin 2 receptor antagonist it is developing in collaboration with Janssen for the treatment of insomnia. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1) protein for the treatment of Parkinson’s disease.